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Abstract
Background: A SNP at position 131, in the FcγRIIa gene, affects the binding of the different IgG
subclasses and may influence the clinical variation seen in patients with falciparum malaria. This
study confirms and extends previous findings, analysing the FcγRIIa (CD32) polymorphism in
relation to the IgG subclass distribution seen among two sympatric tribes living in eastern Sudan,
characterized by marked differences in susceptibility to Plasmodium falciparum malaria.
Methods: Two hundred and fifty Fulani subjects living in an area of meso-endemic P. falciparum
malaria infection were genotyped for the FcγRIIa-131 polymorphism. For comparison, 101 non-
Fulani donors – (Masaleit, Hausa and Four) – living in the same study area, were genotyped. The
levels of plasma antibodies (IgG and subclasses) to four malaria antigens (AMA-1, MSP 2 – 3D7 &
FC27, Pf332-C231) were measured using indirect enzyme-linked immunosorbent assays.
Results: The FcγRIIa-H/H131 genotype was found to be significantly more prevalent in the Fulani
as compared to the non-Fulani ethnic groups (36.0% for Fulani versus 17.8% for non-Fulani,
adjusted OR 3.10, 95% CI 1.61–5.97, P value < 0.001). The Fulani showed lower anti-malarial IgG1
and IgG3 antibody levels as compared to the non-Fulani and higher levels of IgG2 antibodies.
Conclusion: The FcγRIIa-H/H131 genotype and H131 allele is at higher frequency in the Fulani
ethnic group. The H/H131 genotype was consistently associated with higher levels of anti-malarial
IgG2 and IgG3 antibodies, while the R/R131 genotype was associated with higher levels of IgG1
antibodies.
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Background
One of the most common causes of morbidity and mor-
tality in African children is Plasmodium falciparum malaria
[1]. For the last 10 years field studies have been carried out
in Daraweesh village in eastern Sudan, aimed at under-
standing the population dynamics and human immune
responses to malaria infections in an area of seasonal and
unstable malaria transmission. Studies in Daraweesh have
demonstrated that a significant proportion of the popula-
tion harbours asymptomatic infections detectable by a
rise in anti-malarial antibody titres during the transmis-
sion season [2-4].
Naturally acquired antibodies are important for protec-
tion against asexual blood stages of malaria, as shown by
passive transfer of immunoglobulin gamma (IgG) from
African malaria-immune adults to Thai malaria-naïve
patients [5]. FcγRIIa, one of three receptors for human
IgG, is expressed on the surface of all types of cells of the
immune system. FcγRIIa is a low-affinity receptor for
monomeric IgG, but binds IgG immune complexes effi-
ciently [6]. FcγRIIa is believed to play a major role in elic-
iting monocyte and macrophage-mediated effector
responses against blood-stage malaria parasites. A single
nucleotide polymorphism (SNP) G/A, causes an arginine
(R) to be replaced with histidine (H) at position 131,
defines two allotypes, which differ in their avidity for
complexed human IgG2 and IgG3 [7]. The H131 receptor
is high-binding for IgG2, while the R131 receptor is low-
binding for this subclass. IgG2 is a poor activator of the
classical complement pathway, and since FcγRIIa-H131 is
essential for handling IgG2 immune complexes therefore
this SNP might have an impact on the outcome of the
immune response to P. falciparum [6].
Previous studies involving the Fulani ethnic group in
Burkina Faso and Mali have shown that these individuals
are less affected by clinical malaria than individuals from
other sympatric ethnic groups [8-13]. In addition, the
Fulani in Sudan were significantly less parasitized than
the individuals of sympatric non-Fulani ethnic groups
[14], corroborating the results previously obtained in
Burkina Faso and Mali [8,12,13]. The lower susceptibility
to P. falciparum malaria seen in the Fulani could, however,
not be explained by gene polymorphisms previously asso-
ciated with malaria resistance, i.e. HbS, HbC, alpha-thal,
G6PD and HLA [11,15]. In a longitudinal study of a
Fulani population resident in eastern Sudan, an unex-
pected variation was seen regarding individual disease
susceptibility and outbreak severity [16]. In this popula-
tion, it was recently shown that FcγRIIa (CD32) and Hb
AS polymorphisms [17], as well as GM and KM allotypes
of IgG, differ significantly between the Fulani and non-
Fulani ethnic groups [14]. On the basis of these observa-
tions, it may be hypothesized that the FcγRIIa genotype,
GM and KM allotypes may contribute to the interethnic
differences in malaria susceptibility, possibly in part by
influencing the IgG subclass pattern of the anti-malarial
antibodies.
In this study, the influence of the FcγRIIa-R/H131 poly-
morphisms on the IgG subclass patterns of antibodies to
four malaria vaccine candidate antigens was analysed in
the Fulani and their sympatric non-Fulani ethnic groups
in eastern Sudan.
Methods
Study area
A detailed description of the study area has been previ-
ously reported [16,18,19]. The study was carried out
before the rainy seasons between 2004 and 2006 in the
Daraweesh village, Gedaref State in eastern Sudan. Daraw-
eesh is 450 km from Khartoum and 16 km from Gedaref
town. It is inhabited by approximately 420 Arabic speak-
ers of Fulani ethnic origin whose ancestors settled in this
area about a century ago [20]. The village economy is
based on agriculture. Malaria transmission is markedly
seasonal and unstable and annual peak parasite preva-
lence ranges from 1 to 40% in different years. The trans-
mission is hypo-endemic and the acquisition of clinical
immunity with age is not as obvious as seen in holo-
endemic areas and thus malaria remains a problem in all
age groups [20]. Plasmodium falciparum is responsible for
>96% malaria cases, the remainder being Plasmodium
vivax and Plasmodium malariae. Anopheles arabiensis is the
sole vector.
Study population
This study is a part of a longitudinal study of infection and
immunity to malaria in Daraweesh, which has been going
on since 1990. The study received approval from the ethi-
cal Committee of the University of Khartoum and
national clearance from the Sudanese Ministry of Health.
In this Daraweesh population, who are of Fulani origin, a
study showed distinctly variable level of disease suscepti-
bility [16]. In the present study, data and samples from a
cohort of 250 permanent residents (162 female, 88 male;
median of age in 2005, 15.5 years, with the range 4–75
years), monitored clinically and parasitologically by pas-
sive case detection for up to 11 years were used. During
the malaria transmission season, all individuals feeling
unwell reported to the health team that was present in the
village on daily basis. A total of 101 subjects from the
sympatric non-Fulani ethnic neighbours – Masaleit
(51%), Hausa (27.7%) and Four (21.8%) [14], were con-
secutively selected for the study (60 female, 41 male;
median of age in 2005, 17.0 years, with the range 2–55
years). All blood samples were collected before the rainy
season and all individuals were asymptomatic and nega-
tive for Plasmodium parasites.Malaria Journal 2009, 8:43 http://www.malariajournal.com/content/8/1/43
Page 3 of 10
(page number not for citation purposes)
Blood collection for genotype and ELISA analysis
Three ml of peripheral blood were collected from the indi-
viduals into vacuum EDTA tubes. The collected blood
samples were centrifuged for 15 minutes at 250 g. The
layer of white cells on top of red blood cells were collected
into sterile cryotubes and stored frozen at -20°C for DNA
extraction and FcγRIIa genotyping. The plasma was trans-
ferred into cryotubes stored at -20°C until use for anti-
body detection.
DNA purification
Genomic DNA was purified from the buffy-coat cells
using a modified version of the Chelex-100 method and
then stored at -20°C [21]. In brief, 25 ml from the cells
were incubated overnight at 4°C in 1 ml of 0.5% saponin
in 1× phosphate-buffered saline (PBS). The pellet was
washed for 30 min with PBS at 4°C, and the supernatant
discarded. The pellet was boiled in 120 ml of 5% Chelex-
100 in water for 15 min, and the DNA was collected in the
supernatants after centrifugation at 250 g for 3 min.
Genotyping of the FcγRIIa gene
The FcγRIIa genotype was determined using a modified
version of a polymerase chain reaction (PCR) method
[22]. The PCR conditions were as follows: one cycle at
96°C for five minutes, 30 cycles at 94°C for 30 sec and
56°C for 30 sec, and one cycle at 72°C for 45 sec. The PCR
product was digested for 2 h at 37°C using the restriction
enzyme BstUI (Fermentas Inc. MD, USA), according to the
manufacturer's recommendation. The enzyme cuts at one
site in the R131 allele and twice in the H131 allele. The
fragments were resolved by electrophoresis in a 2% agar-
ose gel.
Measurement of antibodies
The levels of serum antibodies (IgG total and subclasses)
to four malaria antigens (AMA-1, MSP 2 – 3D7 & FC27,
Pf332-C231) were measured using enzyme-linked immu-
nosorbent assays (ELISA), mainly as previously described
[23]. Briefly, EIA/RIA plates (Costar, MA, USA) were
coated with AMA-1 at 1 μg/ml, 3D7-MSP 2 and FC27-MSP
2 at 1 μg/ml, and Pf332-C231 at 5 μg/ml. The AMA-1 pro-
tein, which has an N-terminal hexa-His tag, was expressed
in Escherichia coli and refolded in vitro [24]. Both the 3D7
and FC27 forms of MSP 2 were expressed in E. coli with C-
terminal hexa-His tags. The expression and purification of
these proteins will be described elsewhere (Hobba et al,
manuscript in preparation). The recombinant Pf332-
C231 corresponds to a 231-amino acid fragment in the C-
terminal part of Pf332 [25]. The plates were incubated
overnight at 4°C, and then blocked for 2 hrs with 0.5%
bovine serum albumin (BSA) diluted in carbonate buffer
(pH 9.6). Plasma samples diluted in incubation buffer
(PBS + 0.5% BSA), 1:1,000 (IgG) and 1:400 (IgG1–4),
were added in duplicate and incubated for 1 h at 37°C.
The plates were than washed four times, and bound IgG
antibodies were detected with goat anti-human IgG-ALP
(1:2000) (Mabtech, Nacka, Sweden). IgG subclasses were
analysed with their respective biotin conjugated mouse
anti-human subclass specific monoclonal antibodies:
mouse anti-human IgG1 1:1,000 (M15015, Clone NL16,
SkyBio, Bedfordshire, UK), mouse anti-human IgG2
1:3,000 (555874, Pharmingen, Erembodegem, Belgium),
mouse anti-human IgG3 1:1,000 (MH 1532, Caltag labo-
ratories, Paisley, UK) and mouse anti-human IgG4
1:2,000 (B3648, Sigma, St. Louis, USA). Alkaline phos-
phatase (ALP) conjugated streptavidin (Mabtech) diluted
1:2,000 was added to detect bound antibodies of IgG2–4,
while ALP-conjugated to goat anti-mouse Ig (Dakopatts,
Glostrup, Denmark; 1:1,000) were used for IgG1 antibod-
ies and the plates were developed with nitrophenyl phos-
phate (Sigma-Aldrich Chemie GmbH, Steinheim,
Germany). The absorbance was read at 405 nm using a
Vmax™ Kinetic microplate reader (Molecular devices,
Menlo Park, USA) and the antibody concentrations were
deduced from the log-log correlative coefficient of each
IgG subclass standard curve (six dilutions of myeloma
proteins of IgG1–4 subclasses), ranging from 0.01 to 3 μg/
ml for IgG1, 0.001 to 0.3 μg/ml for IgG2, 0.001 to 0.1 μg/
ml for IgG3 and 0.01 to 1 μg/ml for IgG4 according to the
manufacturer's recommendation (Biogenesis, Poole, Eng-
land).
Statistical analysis
FcγRIIa genotype, allele frequencies and antibody levels
were analysed using SPSS version 10.0 (SPSS, Inc, Chi-
cago, IL, USA). Logistic regression analysis was performed
with age, sex and antibodies modelled as binary dummy
variables (ranked into third distribution using the first
third as the reference indicator). Associations were quan-
tified using odds ratios [OR] with 95% confidence inter-
vals [CI] that did not cross 1.00 with P value < 0.05,
defined as statistically significant. The FcγRIIa-His/Arg131
group was used as a reference in the analyses, because this
genotype is the most prevalent in human populations
[26]. An overall comparison of allele frequency using a 2
× 2 chi-square test was performed using the same soft-
ware.
Results
A total of 351 individuals were included in the study, 202
(63.2%) females and 129 (36.8) males, with an overall
age range of 2 to 75 years. No donor had any malaria par-
asites detectable by microscopy at the time of sampling;
this result was confirmed by PCR screening of the samples
(not listed).
FcγRIIa-R/H131 genotype and allele frequencies in the 
sympatric ethnic groups
All individuals of the two study groups were genotyped
for the FcγRIIa-H/R131 SNP. The H/H131 genotype was at
higher frequency in the Fulani than in the non-Fulani eth-Malaria Journal 2009, 8:43 http://www.malariajournal.com/content/8/1/43
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nic group (36.0% for Fulani versus 17.8% for non-Fulani;
unadjusted OR 2.67, 95% CI 1.48–4.83, P < 0.001 and
adjusted OR 3.10, 95% CI 1.61–5.97, P < 0.001) (Tables
1 and 2). In contrast, there were no differences between
the two groups in the frequency of R/R 131 genotype
(17.6% for Fulani versus 20.8% non-Fulani; adjusted OR
0.99, 95% CI 0.52–1.89, P value 0.98) (Tables 1 and 2).
However, when using the H/H131 genotype as a reference
group in the statistical analysis, the heterozygote H/R131
genotype was found to be statistically significantly at
higher frequency in the non-Fulani than in Fulani (46.4%
for Fulani versus 61.4% for non-Fulani; adjusted OR 0.34,
95% CI 0.18–0.62, P < 0.001) (Table 2). A similar signifi-
cant difference was seen for the R/R131 genotype, also
being at higher frequency in non-Fulani as compared with
Fulani (17.6% for Fulani versus 20.8% for non-Fulani;
adjusted OR 0.36, 95% CI 0.17–0.77, P < 0.001) (Table
2).
A genetic difference between the two ethnic groups was
also evident when comparing the FcγRIIa-R/H131 allele
frequencies, the H131 allele being more common in the
Fulani (0.60 for Fulani versus 0.49 non-Fulani; OR 1.54,
95% CI 1.09–2.17, P value 0.01) (Table 1). No such
interethnic difference was seen for the R131 allele. The
overall genotypic frequencies did not differ statistically
among the different age groups within the ethnic groups,
neither in the Fulani (P value 0.26) nor in the non-Fulani
(P value 0.59). No gender dependent differences in geno-
type frequencies were seen (P = 0.61).
IgG antibody reactivities
In this study, antibody responses to four P. falciparum
blood-stage antigens, AMA-1, MSP2 – 3D7, – FC27 and
Pf332-C231, were analysed in the Fulani and the non-
Fulani ethnic groups. There were no statistically signifi-
cant differences in anti-malarial total IgG antibody levels
between the ethnic groups, and therefore the following
analyses were limited only to the IgG subclasses. In gen-
eral, IgG1 and IgG3 subclass antibodies were found to be
at higher levels than IgG2 and IgG4 antibodies in both
ethnic groups. However, the antibody levels varied for the
different antigens. When comparing the antibody levels
between the two ethnic groups, the non-Fulani showed
significantly higher levels of IgG1 antibodies reactive with
AMA-1 (P < 0.001), and also tended to have higher IgG3
antibody levels (P = 0.062) (Table 3). The IgG2 antibody
responses reactive with AMA-1 were, however, statistically
significantly higher in the Fulani than in the non-Fulani
ethnic group (P = 0.024) (Table 3). While antibodies reac-
tive with MSP2-3D7 showed a similar pattern of intereth-
nic differences in IgG subclass levels as those reactive with
AMA-1, IgG1 antibodies reactive with MSP2-FC27 were at
higher levels in the Fulani as compared to the non-Fulani
(P = 0.041) (Table 3). Regarding Pf332-C231 reactive
antibodies, IgG3 and IgG4 subclasses were significantly
higher in the non-Fulani than in the Fulani (P < 0.001)
(Table 3). No differences in levels of antibodies of the dif-
ferent IgG subclasses were seen among the different eth-
nicities within the non-Fulani group.
FcγRIIa genotype and P. falciparum-specific IgG subclass 
distribution
In order to see if the FcγRIIa genotype affected the specific
IgG subclass levels, using four different malarial antigens,
the relationship between FcγRIIa genotype and IgG anti-
body subclasses was analysed. For the study population as
a whole, including both the Fulani and the non-Fulani
individuals, the H/H131 genotype was statistically signif-
icantly associated with higher levels of IgG2 (P < 0.001),
IgG3 (P = 0.01) and IgG4 antibodies against AMA-1 (P =
0.01) (Table 4). Furthermore, there was a trend for an
association of the R/R131 genotype with higher levels of
IgG1 antibodies against AMA-1 (P = 0.05) (Table 4).
Interethnic comparison of AMA-1 reactive antibodies in
relation to FcγRIIa genotypes showed that non-Fulani H/
H 131 carriers had significantly higher levels of IgG1
(adjusted OR 0.04, 95% CI 0.02–0.12; P < 0.001) and
IgG3 (adjusted OR 0.31, 95% CI 0.17–0.57; P < 0.001)
(Table 5). No such interethnic differences were found for
the IgG2 and IgG4 antibody subclasses.
Regarding antibodies reactive with MSP2-3D7 or -FC27 in
the study population as a whole, a similar pattern as with
AMA-1 reactive antibodies was seen. The H/H 131 geno-
type carriers showed statistically significantly higher levels
of IgG2 (P < 0.001 and = 0.01, respectively), IgG3 (P =
0.01 for both antigens) and IgG4 (P = 0.01 and < 0.001,
respectively), while the R/R 131 genotype carriers showed
higher levels of IgG1 antibodies (P = 0.01 for both anti-
gens) (Table 4).
Interethnic comparison of MSP2-3D7 reactive antibodies
in relation to FcγRIIa genotypes showed that non-Fulani
H/H 131 carriers had significantly higher levels of IgG1
Table 1: Distribution of the FcγRIIa-131 genotypes and allele 
frequency in the sympatric ethnic groups
FcγRIIa genotypes
Ethnic H/H131 H/R131 R/R131
Fulani n (%) 90 (36.0%) 116 (46.4%) 44 (17.6%)
Non-Fulani n (%) 18 (17.8%) 62 (61.4%) 21 (20.8%)
Allele Frequency* H131 R131
Fulani 0.60 0.40
Non-Fulani 0.49 0.51
* 0.60 for Fulani versus 0.40 non-Fulani; OR 1.54, 95% CI (1.09–2.17), 
P value 0.01Malaria Journal 2009, 8:43 http://www.malariajournal.com/content/8/1/43
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(adjusted OR 0.10, 95% CI 0.03–0.20; P < 0.001) and
IgG3 (adjusted OR 0.49, 95% CI 0.26–0.91; P value 0.03),
while Fulani H/H 131 carriers showed higher levels of
IgG2 (adjusted OR 2.43, 95% CI 1.32–4.47; P < 0.001)
and IgG4 antibodies (adjusted OR 2.76, 95% CI 1.45–
5.26; P < 0.001) (Table 5). In contrast, an interethnic com-
parison for MSP2-FC27 reactive antibodies, showed that
the non-Fulani H/H 131 genotype carriers had signifi-
cantly higher levels of IgG2 (adjusted OR 0.45, 95% CI
0.24–0.85; P = 0.01) and IgG3 (adjusted OR 0.13, 95% CI
0.10–0.26; P < 0.001) than the Fulani, while no signifi-
cant interethnic differences were found regarding IgG1
and IgG4 antibody levels with any of the genotypes (Table
5).
Regarding antibodies reactive with Pf332-C231 in the
study population as a whole, the H/H131 genotype was
statistically significantly associated with higher levels of
IgG2 (P = 0.01) and IgG3 (P < 0.001) (Table 4). Further-
more, the R/R131 genotype was statistically significantly
associated with higher levels of IgG1 antibodies reactive
with this antigen (P = 0.01) (Table 4).
Interethnic comparison of Pf332-C231 reactive antibod-
ies in relation to FcγRIIa genotypes showed that non-
Fulani H/H 131 carriers had significantly higher levels of
IgG2 (adjusted OR 0.22, 95% CI 0.11–0.44; P < 0.001)
and IgG4 (adjusted OR 0.10, 95% CI 0.03–0.20; P <
0.001), IgG3 antibodies were at significantly higher levels
in H/H 131 carriers of the Fulani group (adjusted OR
4.25, 95% CI 2.28–7.91; P < 0.001) (Table 5).
Discussion
The present study confirms and extends the previous find-
ing in the same study population, that the prevalence of
the FcγRIIa-H/H131 genotype and the H131 allele are sta-
tistically significantly higher in Fulani than in sympatric
non-Fulani children [17]. The prevalence of both the
FcγRIIa-H/H131 genotype and the H131 allele was similar
in the different age groups of the Fulani, indicating that
the H131 allele carriage has no evident influence on the
survival of the individuals. Interestingly, a similar higher
frequency of the H/H131 genotype and H131 allele was
recently observed also in the Fulani living in Mali, com-
pared to the sympatric ethnic group, the Dogon [27]. It is
well established that the Fulani in Mali and Burkina Faso
are less affected by malaria than other sympatric ethnic
groups, the Dogon and the Mossi/Rimaibé, respectively
[12]. Similarly, the Fulani in the present study site has
been shown to have lower P. falciparum parasite densities
and parasite rates than the neighbouring ethnic group, the
Masaleit [17]. Whether the FcγRIIa-R/H131 polymor-
phism is a contributing factor in the observed ethnic dif-
ferences in susceptibility to malaria remains to be studied
in different epidemiological settings.
Contrasting results have been reported regarding associa-
tions of FcγRIIa-R/H131 genotypes with malaria disease
outcomes [6]. Thus, one study observed an association
between the H/H131 genotype and susceptibility to severe
Table 2: Logistic regression analysis of FcγRIIa genotypes in Fulani compared with non-Fulani ethnic groups
Unadjusted Odds ratio (95% CI) p value Adjusted* Odds ratio (95% Cl) p value
H/H131 2.67 (1.48–4.83) < 0.001 3.10 (1.61–5.97) < 0.001
R/H131 1.00 1.00
R/R131 1.12 (0.61–2.05) 0.71 0.99 (0.52–1.89) 0.98
H/H131 1.00 1.00
R/H131 0.37 (0.21–0.68) < 0.001 0.34 (0.18–0.62) < 0.001
R/R131 0.42 (0.20–0.87) 0.02 0.36 (0.17–0.77) 0.01
*Adjustment of Odds ratio was performed for sex, age
Table 3: Logistic regression analysis of immunoglobulin classes in 
Fulani and Non-Fulani ethnic groups
Antigen IgG subclass OR† (95% CI) p value
AMA-1 IgG1 1.2 (1.1 to 1.3) < 0.001
IgG2 0.6 (0.3 to 0.9) 0.024
IgG3 2.2 (0.9 to 5.4) 0.062
IgG4 0.4 (0.1 to 1.2) 0.113
3D7-MSP2 IgG1 1.1 (1.0 to 1.2) 0.015
IgG2 0.6 (0.4 to 0.9) 0.018
IgG3 1.0 (1.0 to 1.0) 0.069
IgG4 0.1 (0.05 to 0.3) < 0.001
FC27-MSP2 IgG1 0.5 (0.2 to 0.9) 0.041
IgG2 2.9 (1.2 to 7.1) 0.016
IgG3 2.2 (1.4 to 3.3) < 0.001
IgG4 0.5 (0.2 to 1.3) 0.159
Pf332-C231 IgG1 2.5 (0.8 to 6.8) 0.081
IgG2 1.0 (0.9 to 1.0) 0.978
IgG3 2.7 (1.6 to 4.3) < 0.001
IgG4 8.1 (3.5 to 18.6) < 0.001
† OR represent odds ratios while CI represents confidence intervals. 
Fulani were assigned 0 while non-Fulani were assigned 1 in the logistic 
regression analysis. OR above 1 represented value associated to non-
Fulani while less than 1 value represented Fulani.Malaria Journal 2009, 8:43 http://www.malariajournal.com/content/8/1/43
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Table 4: Logistic regression analysis of FcγRIIa-H/R131 genotypes in relation to anti-malarial IgG subclasses in the combined study 
populations
Anti-malarial antibodies FcγRIIa-H/R131 genotypes OR† (95% CI) p value
AMA-1
IgG1 H/H 1.15 (0.57–2.31) 0.70
H/R 1
R/R 1.91 (1.00–3.64) 0.05
IgG2 H/H 2.65 (1.43–4.91) < 0.001
H/R 1
R/R 1.34 (0.69–2.61) 0.38
IgG3 H/H 2.26 (1.21–4.22) 0.01
H/R 1
R/R 1.38 (0.70–2.72) 0.35
IgG4 H/H 2.93 (1.33–6.41) 0.01
H/R 1
R/R 1.15 (0.53–2.48) 0.72
3D7-MSP2
IgG1 H/H 0.10 (0.03–0.20) < 0.001
H/R 1
R/R 0.86 (0.41–1.80) 0.69
IgG2 H/H 2.76 (1.32–4.47) < 0.001
H/R 1
R/R 1.27 (0.66–2.46) 0.48
IgG3 H/H 2.37 (1.28–4.38) 0.01
H/R 1
R/R 1.21 (0.62–2.35) 0.58
IgG4 H/H 2.40 (1.29–4.45) 0.01
H/R 1
R/R 1.47 (0.74–2.92) 0.27
FC27-MSP2
IgG1 H/H 1.26 (0.65–2.43) 0.50
H/R 1
R/R 2.38 (1.29–4.39) 0.01
IgG2 H/H 2.37 (1.28–4.38) 0.01
H/R 1
R/R 1.21 (0.62–2.35) 0.58
IgG3 H/H 2.86 (1.50–5.46) < 0.001
H/R 1
R/R 1.45 (0.70–3.02) 0.32
IgG4 H/H 2.46 (1.33–4.55) < 0.001
H/R 1
R/R 1.77 (0.66–2.48) 0.47
Pf332-C231
IgG1 H/H 1.33 (0.68–2.59) 0.40
H/R 1
R/R 2.43 (1.31–4.50) 0.01Malaria Journal 2009, 8:43 http://www.malariajournal.com/content/8/1/43
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malaria [28], while others found R/R131 genotype carriers
to be less likely to be at risk for high density P. falciparum
infection, compared to the R/H131 heterozygotes [1,29].
Another previous report has associated the H/H131 geno-
type with protection against malaria [1]. However, con-
trasting results also with regard to the R/R131 genotype
and protection from malaria have been reported [28-31].
The FcγRIIa-R/R131 genotype in Sudanese patients was
recently shown to be associated with higher risk to
develop severe malaria [32], while in an Indian popula-
tion, the H/H131 genotype was significantly associated
with protection from malaria disease manifestation [33].
The discrepant results in this context may most likely be
explained by genetic differences between the populations
studied, as well as differences in gene-environment inter-
actions and in patterns of malaria transmission in the dif-
ferent study areas.
Several studies in Burkina Faso and Mali have shown that
the Fulani have significantly higher levels of anti-malarial
antibodies than other sympatric ethnic groups [9,10,13],
including antibodies of all the IgG subclasses, except IgG4
[8]. In contrast, in the present study, the non-Fulani had
significantly higher levels of anti-malarial IgG1 and IgG3
antibodies than the Fulani for three of the four antigens
studied, but not for MSP2-FC27. The Fulani, tended to
have significantly higher levels of anti-malarial IgG2 anti-
bodies than the non-Fulani group. These discrepant
results seen in Burkina Faso, Mali and Sudan may most
likely be explained by differences in patterns of malaria
transmission in the different study areas [14,16-19]. It
should be recalled that Sudan is a country characterized
by hypo/meso-endemicity, with seasonal and unstable
malaria transmission, unlike Burkina Faso and Mali, char-
acterized with hyper/holo-endemic malaria transmission
[8]. In Daraweesh an entomological inoculation rate
(EIR) of one infective bite/year has been estimated based
on surveys in drought-free years [34]. Almost all malaria
cases in Daraweesh are clinically uncomplicated, proba-
bly because of continuous monitoring by the health team
that visits the village on a daily basis and provides free
drug treatment [16,19].
While the FcγRIIa-R131 molecule shows a similar binding
of the cytophilic subclasses IgG1 and IgG3 [35,36], the
H131 receptor binds IgG3 more efficiently and is the only
FcγR that binds IgG2 efficiently [7,37-40]. Thus, in the
presence of the FcγRIIa-H131 receptor, IgG2 antibodies
should also be considered as cytophilic, and thus this
receptor is essential for effective IgG2-mediated cellular
activation. The present study indicates that the differential
recognition of the IgG subclasses by the R131 and H131
FcγRIIa may have an impact on the pattern of IgG sub-
classes in the anti-malarial immune response. Higher lev-
els of IgG2 and IgG3 antibodies were associated with the
H/H genotype, while higher levels of IgG1 antibodies
were associated with the R/R131 genotype. In line with
this, the Fulani showed a higher frequency of the FcγRIIa-
H131 allele and higher levels of anti-malarial IgG2 anti-
bodies than sympatric non-Fulani ethnic groups. A similar
higher frequency of the FcγRIIa-H131 allele and a higher
proportion of IgG2 among the anti-malarial antibodies,
were recently observed in the Fulani in Mali compared to
a sympatric non-Fulani ethnic group [27].
There is accumulating evidence for IgG1 and IgG3 anti-
bodies playing an important role in protection against
malarial disease [41]. However, the contribution of para-
site-reactive IgG2 antibodies in protection against clinical
malaria [32,42] and/or in susceptibility to disease [35,43]
has been indicated in some epidemiological settings. In
Burkina Faso, the association between anti-malarial IgG2
antibodies and protection against malaria, was suggested
to be due to the relatively high prevalence of the IgG2
binding H/H131 genotype in that study population [42].
Whether the higher levels of anti-malarial IgG2 antibodies
and the higher frequency of the FcγRIIa-H131 allele in the
Fulani contributes to the lower susceptibility to malaria in
this ethnic group as compared to sympatric non-Fulani
ethnic groups, remains to be investigated in extended epi-
demiological studies.
Conclusion
The present study confirms and extends the previous find-
ings that the FcγRIIa-H/H131 genotype and the H131
IgG2 H/H 2.26 (1.21–4.22) 0.01
H/R 1
R/R 1.38 (0.70–2.72) 0.35
IgG3 H/H 2.44 (1.32–4.51) < 0.001
H/R 1
R/R 1.18 (0.61–2.30) 0.62
IgG4 H/H 1.79 (0.92–3.49) 0.10
H/R 1
R/R 1.33 (0.59–2.97) 0.50
Table 4: Logistic regression analysis of FcγRIIa-H/R131 genotypes in relation to anti-malarial IgG subclasses in the combined study 
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Table 5: Logistic regression analysis of FcγRIIa-H/R131 genotypes in relation to anti-malarial IgG subclasses in Fulani compared with 
non-Fulani groups
Anti-malarial antibodies FcγRIIa-H/R131 genotypes OR† (95% CI) p value
AMA-1
IgG1 H/H 0.04 (0.02–0.12) < 0.001
H/R 1
R/R 0.86 (0.42–1.78) 0.69
IgG2 H/H 0.70 (0.35–1.37) 0.30
H/R 1
R/R 0.61 (0.34–1.11) 0.10
IgG3 H/H 0.31 (0.17–0.57) < 0.001
H/R 1
R/R 0.69 (0.34–1.38) 0.30
IgG4 H/H 0.59 (0.30–1.15) 0.12
H/R 1
R/R 0.90 (0.41–1.95) 0.78
3D7-MSP2
IgG1 H/H 0.10 (0.03–0.20) < 0.001
H/R 1
R/R 0.86 (0.41–1.80) 0.69
IgG2 H/H 2.43 (1.32–4.47) < 0.001
H/R 1
R/R 0.83 (0.41–1.69) 0.61
IgG3 H/H 0.49 (0.26–0.91) 0.03
H/R 1
R/R 0.81 (0.40–1.63) 0.55
IgG4 H/H 2.76 (1.45–5.26) < 0.001
H/R 1
R/R 0.59 (0.28–1.25) 0.17
FC27-MSP2
IgG1 H/H 0.53 (0.28–1.01) 0.10
H/R 1
R/R 0.86 (0.42–1.78) 0.68
IgG2 H/H 0.45 (0.24–0.85) 0.01
H/R 1
R/R 0.70 (0.35–1.37) 0.30
IgG3 H/H 0.13 (0.10–0.26) 0.01
H/R 1
R/R 0.76 (0.37–1.57) 0.46
IgG4 H/H 0.70 (0.36–1.39) 0.31
H/R 1
R/R 0.97 (0.54–1.74) 0.92
Pf332-C231
IgG1 H/H 1.25 (0.67–2.30) 0.48
H/R 1
R/R 0.72 (0.36–1.44) 0.36Malaria Journal 2009, 8:43 http://www.malariajournal.com/content/8/1/43
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allele are more frequent in the Fulani, than in their sym-
patric ethnic neighbours. The Fulani in Sudan had lower
anti-malarial IgG1 and IgG3 antibody levels than the non-
Fulani and higher levels of IgG2 antibodies. The higher
IgG2 antibody levels seen in the Fulani may be due to the
relatively high prevalence for the H/H131 genotype in this
group. Further studies are needed to elucidate if the
FcγRIIa-R/H131 polymorphism may be a contributing
factor to the differential susceptibility to malaria seen in
different ethnic groups.
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